Hospital
The Charlotte-Mecklenburg Hospital Authority
The Charlotte-Mecklenburg Hospital Authority was paid $20.10M by Medicaid between Jan 2019 and Dec 2024, across 150 billing codes. Its largest line is 99283, emergency room visit (moderate) — 23% of everything it billed.
33Billing provider infoTHE CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY
CHARLOTTE, NC 28210
CHARLOTTE, NC 28210
33aNPI1417432840assigned 10/02/2018
33bProvider typeGeneral Acute Care Hospital
28Total paid$20.10M
24GClaims381,407
24DCodes billed150
24AFirst – last monthJan 2019 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in North Carolina
Rank by total paid#31 of 92
Median peer was paid$11.47M
This provider vs. median1.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official DEFURIO, ANTHONY controls 19+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 69,596 | $2.52M | |
| 2020 | 51,370 | $1.97M | |
| 2021 | 69,124 | $3.27M | |
| 2022 | 72,284 | $4.01M | |
| 2023 | 59,547 | $4.28M | |
| 2024incomplete | 59,486 | $4.06M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 23% | 30,730 | 28,824 | $4.64M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 19% | 29,825 | 27,419 | $3.77M |
| J3490 | Unclassified drugs | 13% | 30,193 | 14,096 | $2.55M |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 4.8% | 8,025 | 7,531 | $969K |
| 80053 | Comprehensive metabolic panel | 4.6% | 19,613 | 17,423 | $925K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 4.3% | 11,811 | 10,612 | $870K |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | 3.8% | 13,193 | 6,383 | $773K |
| J2270 | Injection, morphine sulfate, up to 10 mg | 2.9% | 2,529 | 1,922 | $574K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 2.6% | 1,637 | 1,507 | $521K |
| 80048 | Basic metabolic panel (calcium, ionized) | 2.5% | 8,539 | 6,981 | $502K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.5% | 3,476 | 2,798 | $294K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 1.4% | 2,746 | 2,409 | $285K |
138 more codes
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.4% | 2,878 | $282K |
| J8597 | Antiemetic drug, oral, not otherwise specified | <1% | 1,155 | $180K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 2,075 | $165K |
| 87070 | <1% | 1,158 | $165K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 803 | $129K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 6,690 | $127K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 4,714 | $123K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 10,747 | $121K |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 1,074 | $114K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,668 | $110K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 232 | $106K |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 817 | $100K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 765 | $95K |
| G0378 | Hospital observation service, per hour | <1% | 2,801 | $94K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 18,946 | $91K |
| 81025 | <1% | 7,737 | $90K | |
| 87081 | <1% | 1,108 | $89K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 4,123 | $83K |
| 81003 | <1% | 6,533 | $69K | |
| 82962 | <1% | 3,142 | $67K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 1,974 | $62K |
| 85027 | <1% | 9,406 | $61K | |
| 87486 | <1% | 311 | $60K | |
| 87210 | <1% | 1,594 | $57K | |
| 81001 | <1% | 6,478 | $56K | |
| 84702 | <1% | 1,911 | $54K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 340 | $53K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 10,337 | $52K |
| 71045 | Radiologic examination, chest; single view | <1% | 3,029 | $32K |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 83 | $31K |
| 73630 | <1% | 369 | $30K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 145 | $29K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,269 | $28K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 2,558 | $26K |
| S0028 | Injection, famotidine, 20 mg | <1% | 212 | $24K |
| 59025 | Fetal non-stress test | <1% | 1,919 | $24K |
| 81002 | <1% | 1,312 | $20K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,914 | $14K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 890 | $14K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,738 | $14K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 2,643 | $14K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 569 | $13K |
| 73610 | <1% | 165 | $12K | |
| 87430 | <1% | 977 | $12K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 858 | $12K |
| 84484 | <1% | 6,980 | $12K | |
| 76830 | Ultrasound, transvaginal | <1% | 507 | $12K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,141 | $11K |
| 73130 | <1% | 97 | $10K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 324 | $9K |
| 93975 | <1% | 866 | $9K | |
| A9270 | Non-covered item or service | <1% | 14,951 | $8K |
| 93971 | <1% | 349 | $7K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 54 | $7K |
| 73560 | <1% | 130 | $7K | |
| 81000 | <1% | 630 | $7K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 15 | $7K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 506 | $6K |
| 83690 | <1% | 5,445 | $6K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,941 | $6K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,193 | $5K |
| 83735 | <1% | 5,007 | $5K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 91 | $5K |
| 74018 | <1% | 85 | $5K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 6,474 | $5K |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 17 | $5K |
| 73110 | <1% | 40 | $4K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 657 | $4K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 26 | $3K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,415 | $3K |
| 86900 | <1% | 29 | $3K | |
| 86901 | <1% | 646 | $3K | |
| 73562 | <1% | 58 | $3K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 54 | $3K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 372 | $2K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 88 | $2K |
| 83880 | <1% | 1,764 | $2K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,416 | $2K |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 13 | $2K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 17 | $2K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,695 | $2K |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 27 | $2K |
| 76801 | <1% | 49 | $2K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,978 | $2K |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 81 | $2K |
| 0011A | <1% | 22 | $1K | |
| 87581 | <1% | 311 | $1K | |
| 73030 | <1% | 26 | $1K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,369 | $1K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,980 | $1K |
| 82803 | <1% | 311 | $1K | |
| 0012A | <1% | 19 | $1K | |
| 72100 | <1% | 43 | $976.86 | |
| 87077 | <1% | 39 | $907.04 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 6,727 | $861.66 |
| 83605 | <1% | 2,180 | $835.46 | |
| 96376 | <1% | 2,321 | $797.73 | |
| J2704 | Injection, propofol, 10 mg | <1% | 1,596 | $786.97 |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 70 | $766.97 |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 151 | $743.41 |
| 85610 | <1% | 804 | $707.74 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 826 | $649.14 |
| 80076 | <1% | 421 | $580.96 | |
| 80143 | <1% | 35 | $451.43 | |
| 80179 | <1% | 35 | $335.96 | |
| Q3014 | Telehealth originating site facility fee | <1% | 48 | $291.51 |
| J7999 | Compounded drug, not otherwise classified | <1% | 27 | $273.09 |
| 94761 | <1% | 373 | $260.87 | |
| 85379 | <1% | 865 | $248.17 | |
| 76937 | <1% | 124 | $241.62 | |
| 82248 | <1% | 261 | $131.02 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 570 | $104.80 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 137 | $99.79 |
| 99199 | Unlisted special service, procedure or report | <1% | 18 | $95.00 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 77 | $80.59 |
| 87088 | <1% | 116 | $80.20 | |
| 82550 | <1% | 106 | $74.77 | |
| 94760 | <1% | 538 | $59.78 | |
| 85007 | <1% | 30 | $55.42 | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 20 | $31.84 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 94 | $29.36 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 97 | $28.14 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 786 | $23.03 |
| 87186 | <1% | 131 | $9.90 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 221 | $0.23 |
| 84100 | 0% | 49 | $0.00 | |
| 80061 | Lipid panel | 0% | 45 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 63 | $0.00 |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 152 | $0.00 |
| 97161 | 0% | 18 | $0.00 | |
| 87040 | 0% | 230 | $0.00 | |
| 86850 | 0% | 28 | $0.00 | |
| 36410 | 0% | 15 | $0.00 | |
| 87147 | 0% | 49 | $0.00 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 38 | $0.00 |
| 81015 | 0% | 25 | $0.00 | |
| 91301 | 0% | 41 | $0.00 | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | 0% | 17 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDEFURIO, ANTHONY (EXECUTIVE VICE PRESIDENT/CFO)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.